Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 7906 AL 7920

Brexpiprazole's impacts on patients and caregivers in agitation in Alzheimer's dementia

Nakamura Y, Adachi J, Hirota N, Iba K, Sasajima C, Shimizu K, Nakai M, Takahashi K.

Alzheimers Dement. 2025 Jul;21(7):e70522. doi: 10.1002/alz.70522.

Donanemab for Alzheimer's disease: from preclinical research to the clinical application

Dodel R, Frölich L.

Expert Rev Neurother. 2025 Oct;25(10):1151-1163. doi: 10.1080/14737175.2025.2546868. Epub 2025 Aug 25.

Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial

Rajji TK, Baksh SN, Shade DM, Ismail Z, Burhan AM, Okhravi HR, Padala PR, Rosenberg PB, Schneider LS, Porsteinsson AP, Lyketsos CG; S-CitAD Research Group.

Nat Med. 2025 May;31(5):1586-1591. doi: 10.1038/s41591-025-03569-y. Epub 2025 Mar 25.

Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis

Arroyo-Pacheco N, Sarmiento-Blanco S, Vergara-Cadavid G, Castro-Leones M, Contreras-Puentes N.

Ageing Res Rev. 2025 Feb;104:102620. doi: 10.1016/j.arr.2024.102620. Epub 2024 Dec 3.

Efficacy of non-invasive brain stimulation interventions on cognitive impairment: an umbrella review of meta-analyses of randomized controlled trials

Wu M, Song W, Wang X, Teng L, Li J, Zhang J, Li X, Yu D, Jia H, Wang B, Tang Q, Zhu L.

J Neuroeng Rehabil. 2025 Feb 5;22(1):22. doi: 10.1186/s12984-025-01566-3.

Dietary Intake, Mediterranean and Nordic Diet Adherence in Alzheimer's Disease and Dementia: A Systematic Review

Christodoulou CC, Pitsillides M, Hadjisavvas A, Zamba-Papanicolaou E.

Nutrients. 2025 Jan 17;17(2):336. doi: 10.3390/nu17020336.

Deferiprone in Alzheimer Disease: A Randomized Clinical Trial

Ayton S, Barton D, Brew B, Brodtmann A, Clarnette R, Desmond P, Devos D, Ellis KA, Fazlollahi A, Fradette C, Goh AMY, Kalinowski P, Kyndt C, Lai R, Lim YY, Maruff P, O'Brien TJ, Rowe C, Salvado O, Schofield PW, Spino M, Tricta F, Wagen A, Williams R, Woodward M, Bush AI.

JAMA Neurol. 2025 Jan 1;82(1):11-18. doi: 10.1001/jamaneurol.2024.3733.

Pre-treatment subjective sleep quality as a predictive biomarker of tDCS effects in preclinical Alzheimer's disease patients: Secondary analysis of a randomised clinical trial

Lu H, Ni X, Man Chan SS, Cheng CPW, Chan W, Lam LCW.

PLoS One. 2025 Jan 28;20(1):e0317700. doi: 10.1371/journal.pone.0317700. eCollection 2025.

Longitudinally persisting KCNA2-autoantibodies in mild amnestic dementia with Alzheimer´s pathology - Report and literature review

Hansen N, Teegen B, Hirschel S, Fox J, Fitzner D, Wiltfang J, Bartels C.

Behav Brain Res. 2025 Mar 28;482:115437. doi: 10.1016/j.bbr.2025.115437. Epub 2025 Jan 22.

Amyloid Clearance and Transient CSF Aβ40 Reduction in a Case of ARIA-E/H Following Lecanemab Treatment

Naeshiro Y, Kitani-Morii F, Kasai T, Tanaka E, Kobayashi F, Ohara T.

Intern Med. 2026 Apr 1;65(7):1056-1060. doi: 10.2169/internalmedicine.6070-25. Epub 2025 Aug 21.

Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?

Ricaurte-Fajardo A, Ivanidze J, Zhang D, Mahmud M, Yasen W, Ravdin L, Pahlajani S, Leon M, Nordvig AS, Chiang GC.

AJNR Am J Neuroradiol. 2025 Jul 1;46(7):1439-1445. doi: 10.3174/ajnr.A8654.

The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence

Aisen P, Bateman RJ, Crowther D, Cummings J, Dwyer J, Iwatsubo T, Kosco-Vilbois M, McDade E, Mohs R, Scheltens P, Sperling R, Selkoe D.

Alzheimers Dement. 2025 Jan;21(1):e14342. doi: 10.1002/alz.14342. Epub 2024 Nov 13.

Identifying a combination of biomarkers to predict treatment response to nabilone for agitation in Alzheimer's disease - an exploratory post hoc analysis

Wang HJ, Ruthirakuhan M, Andreazza AC, Beroncal EL, Black SE, Gallagher D, Herrmann N, Kiss A, Verhoeff NPLG, Lanctôt KL.

Neurodegener Dis Manag. 2026 Apr-Jun;16(3):263-272. doi: 10.1080/17582024.2025.2587549. Epub 2025 Nov 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias